Angelo Roberto Raccagni, Sara Diotallevi, Riccardo Lolatto, Elena Bruzzesi, Maria Del Carmen Martearena Garcia, Ilaria Mainardi, Caterina Candela, Diana Canetti, Girolamo Piromalli, Nicola Clementi, Roberto Burioni, Antonella Castagna, Silvia Nozza
{"title":"接种 B 型脑膜炎球菌疫苗后的突破性直肠淋病奈瑟菌感染:微生物学和临床特征。","authors":"Angelo Roberto Raccagni, Sara Diotallevi, Riccardo Lolatto, Elena Bruzzesi, Maria Del Carmen Martearena Garcia, Ilaria Mainardi, Caterina Candela, Diana Canetti, Girolamo Piromalli, Nicola Clementi, Roberto Burioni, Antonella Castagna, Silvia Nozza","doi":"10.1093/ofid/ofae562","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>4CMenB appears to be effective in reducing <i>Neisseria gonorrhoeae</i> (Ng) infections. Aims are to assess factors associated with breakthrough rectal Ng after 4CMenB and evaluate clinical and microbiological characteristics of breakthrough infections compared with before vaccination.</p><p><strong>Methods: </strong>This was a retrospective study of gay, bisexual, and other men who have sex with men (GBMSM) vaccinated with 4CMenB (2 doses) between 2017 and 2023 at the San Raffaele Scientific Institute for Research, Hospitalization and Healthcare (IRCCS San Raffaele Scientific Institute), Milan, Italy, and tested for rectal Ng. Rectal Ng infection is considered breakthrough if it occurs >1 month after the second 4CMenB dose and with positive nucleic acid amplification test (NAAT) result. Follow-up was from July 2017 (first 4CMenB vaccination) to November 2023 (data freeze). Rectal Ng was screened with both NAAT and gonococcal-specific cultures. Characteristics of individuals with or without breakthrough Ng and of Ng infections before or after 4CMenB were compared using Mann-Whitney and χ<sup>2</sup>/Fisher tests.</p><p><strong>Results: </strong>Overall, 473 GBMSM vaccinated with 4CMenB were included, with a median age (interquartile range) of 43 (37-51) years; 451 of 473 were living with human immunodeficiency virus. The percentage of NAAT-positive rectal Ng swab samples was 76 of 957 (7.7%) after 4CMenB and 51 of 456 (11.1%) before. Breakthrough rectal Ng after baseline were 76 in 57 of 473 people. People with rectal Ng after 4CMenB were younger, more likely to have a previous sexually transmitted infection, and had more sexual partners than those without (all <i>P</i> < .001). Breakthrough rectal Ng infections were less frequently symptomatic (34.2% vs 66.7%; <i>P</i> = .001) and more likely with negative gonococcal-specific culture (55.3% vs 19.6%; <i>P</i> < .001) compared with before vaccination.</p><p><strong>Conclusions: </strong>Breakthrough rectal Ng infections after 4CMenB were 76 in 57/473 people, preferentially identified in GBMSM with higher-risk sexual behaviors, were less often symptomatic, and more often with negative gonococcal-specific cultures, suggesting lower infection virulence.</p>","PeriodicalId":19517,"journal":{"name":"Open Forum Infectious Diseases","volume":"11 11","pages":"ofae562"},"PeriodicalIF":3.8000,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11532644/pdf/","citationCount":"0","resultStr":"{\"title\":\"Breakthrough Rectal <i>Neisseria gonorrhoeae</i> Infections After Meningococcal B Vaccination: Microbiological and Clinical Features.\",\"authors\":\"Angelo Roberto Raccagni, Sara Diotallevi, Riccardo Lolatto, Elena Bruzzesi, Maria Del Carmen Martearena Garcia, Ilaria Mainardi, Caterina Candela, Diana Canetti, Girolamo Piromalli, Nicola Clementi, Roberto Burioni, Antonella Castagna, Silvia Nozza\",\"doi\":\"10.1093/ofid/ofae562\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>4CMenB appears to be effective in reducing <i>Neisseria gonorrhoeae</i> (Ng) infections. Aims are to assess factors associated with breakthrough rectal Ng after 4CMenB and evaluate clinical and microbiological characteristics of breakthrough infections compared with before vaccination.</p><p><strong>Methods: </strong>This was a retrospective study of gay, bisexual, and other men who have sex with men (GBMSM) vaccinated with 4CMenB (2 doses) between 2017 and 2023 at the San Raffaele Scientific Institute for Research, Hospitalization and Healthcare (IRCCS San Raffaele Scientific Institute), Milan, Italy, and tested for rectal Ng. Rectal Ng infection is considered breakthrough if it occurs >1 month after the second 4CMenB dose and with positive nucleic acid amplification test (NAAT) result. Follow-up was from July 2017 (first 4CMenB vaccination) to November 2023 (data freeze). Rectal Ng was screened with both NAAT and gonococcal-specific cultures. Characteristics of individuals with or without breakthrough Ng and of Ng infections before or after 4CMenB were compared using Mann-Whitney and χ<sup>2</sup>/Fisher tests.</p><p><strong>Results: </strong>Overall, 473 GBMSM vaccinated with 4CMenB were included, with a median age (interquartile range) of 43 (37-51) years; 451 of 473 were living with human immunodeficiency virus. The percentage of NAAT-positive rectal Ng swab samples was 76 of 957 (7.7%) after 4CMenB and 51 of 456 (11.1%) before. Breakthrough rectal Ng after baseline were 76 in 57 of 473 people. People with rectal Ng after 4CMenB were younger, more likely to have a previous sexually transmitted infection, and had more sexual partners than those without (all <i>P</i> < .001). Breakthrough rectal Ng infections were less frequently symptomatic (34.2% vs 66.7%; <i>P</i> = .001) and more likely with negative gonococcal-specific culture (55.3% vs 19.6%; <i>P</i> < .001) compared with before vaccination.</p><p><strong>Conclusions: </strong>Breakthrough rectal Ng infections after 4CMenB were 76 in 57/473 people, preferentially identified in GBMSM with higher-risk sexual behaviors, were less often symptomatic, and more often with negative gonococcal-specific cultures, suggesting lower infection virulence.</p>\",\"PeriodicalId\":19517,\"journal\":{\"name\":\"Open Forum Infectious Diseases\",\"volume\":\"11 11\",\"pages\":\"ofae562\"},\"PeriodicalIF\":3.8000,\"publicationDate\":\"2024-11-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11532644/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Open Forum Infectious Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/ofid/ofae562\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/11/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Forum Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ofid/ofae562","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:4CMenB 似乎能有效减少淋病奈瑟菌 (Ng) 感染。目的:评估接种 4CMenB 后出现突破性直肠感染的相关因素,并评估与接种前相比出现突破性感染的临床和微生物学特征:这是一项回顾性研究,研究对象为2017年至2023年期间在意大利米兰圣拉法埃尔科学研究所(IRCCS San Raffaele Scientific Institute for Research, Hospitalization and Healthcare,IRCCS圣拉法埃尔科学研究所)接种4CMenB疫苗(2剂)并接受直肠Ng检测的男同性恋、双性恋和其他男男性行为者(GBMSM)。如果直肠伍氏感染发生在第二次服用 4CMenB >1 个月后,且核酸扩增检测(NAAT)结果呈阳性,则视为突破性感染。随访时间为 2017 年 7 月(首次接种 4CMenB 疫苗)至 2023 年 11 月(数据冻结)。直肠伍氏菌通过 NAAT 和淋球菌特异性培养进行筛查。使用 Mann-Whitney 和 χ2/Fisher 检验比较了有无突破性 Ng 感染者的特征以及接种 4CMenB 前后 Ng 感染者的特征:总共纳入了 473 名接种了 4CMenB 的 GBMSM,中位年龄(四分位数间距)为 43(37-51)岁;473 人中有 451 人感染了人类免疫缺陷病毒。在 957 份直肠伍氏拭子样本中,4CMenB 后的 NAAT 阳性样本占 76 份(7.7%),而在 4CMenB 前的 456 份样本中,NAAT 阳性样本占 51 份(11.1%)。473 人中有 57 人在基线后出现了 76 例直肠伍氏阳性。与无直肠伍氏感染者相比,4CMenB后直肠伍氏感染者更年轻,更有可能既往感染过性传播疾病,而且性伴侣更多(所有P < .001)。与接种疫苗前相比,突破性直肠伍氏感染出现症状的比例较低(34.2% vs 66.7%; P = .001),淋球菌特异性培养阴性的比例较高(55.3% vs 19.6%; P < .001):结论:接种 4CMenB 后,有 57/473 人发生了突破性直肠伍氏感染,其中 76 人的性行为风险较高,且较少出现症状,淋球菌特异性培养阴性者较多,这表明感染的毒力较低。
Breakthrough Rectal Neisseria gonorrhoeae Infections After Meningococcal B Vaccination: Microbiological and Clinical Features.
Background: 4CMenB appears to be effective in reducing Neisseria gonorrhoeae (Ng) infections. Aims are to assess factors associated with breakthrough rectal Ng after 4CMenB and evaluate clinical and microbiological characteristics of breakthrough infections compared with before vaccination.
Methods: This was a retrospective study of gay, bisexual, and other men who have sex with men (GBMSM) vaccinated with 4CMenB (2 doses) between 2017 and 2023 at the San Raffaele Scientific Institute for Research, Hospitalization and Healthcare (IRCCS San Raffaele Scientific Institute), Milan, Italy, and tested for rectal Ng. Rectal Ng infection is considered breakthrough if it occurs >1 month after the second 4CMenB dose and with positive nucleic acid amplification test (NAAT) result. Follow-up was from July 2017 (first 4CMenB vaccination) to November 2023 (data freeze). Rectal Ng was screened with both NAAT and gonococcal-specific cultures. Characteristics of individuals with or without breakthrough Ng and of Ng infections before or after 4CMenB were compared using Mann-Whitney and χ2/Fisher tests.
Results: Overall, 473 GBMSM vaccinated with 4CMenB were included, with a median age (interquartile range) of 43 (37-51) years; 451 of 473 were living with human immunodeficiency virus. The percentage of NAAT-positive rectal Ng swab samples was 76 of 957 (7.7%) after 4CMenB and 51 of 456 (11.1%) before. Breakthrough rectal Ng after baseline were 76 in 57 of 473 people. People with rectal Ng after 4CMenB were younger, more likely to have a previous sexually transmitted infection, and had more sexual partners than those without (all P < .001). Breakthrough rectal Ng infections were less frequently symptomatic (34.2% vs 66.7%; P = .001) and more likely with negative gonococcal-specific culture (55.3% vs 19.6%; P < .001) compared with before vaccination.
Conclusions: Breakthrough rectal Ng infections after 4CMenB were 76 in 57/473 people, preferentially identified in GBMSM with higher-risk sexual behaviors, were less often symptomatic, and more often with negative gonococcal-specific cultures, suggesting lower infection virulence.
期刊介绍:
Open Forum Infectious Diseases provides a global forum for the publication of clinical, translational, and basic research findings in a fully open access, online journal environment. The journal reflects the broad diversity of the field of infectious diseases, and focuses on the intersection of biomedical science and clinical practice, with a particular emphasis on knowledge that holds the potential to improve patient care in populations around the world. Fully peer-reviewed, OFID supports the international community of infectious diseases experts by providing a venue for articles that further the understanding of all aspects of infectious diseases.